Piper Sandler raised the firm’s price target on Quest Diagnostics (DGX) to $200 from $190 following quarterly results. The firm keeps a Neutral rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $205 from $195 at Truist
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley
- Quest Diagnostics price target raised to $195 from $190 at Barclays
- Quest Diagnostics Reports Strong Q3 2025 Results
- Quest Diagnostics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating